<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5300">
  <stage>Registered</stage>
  <submitdate>19/11/2015</submitdate>
  <approvaldate>19/11/2015</approvaldate>
  <nctid>NCT02636699</nctid>
  <trial_identification>
    <studytitle>Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy</studytitle>
    <scientifictitle>A Double-blind, Placebo-controlled, Randomized Phase 3 Pivotal Trial to Assess the Efficacy and Safety of Peanut Epicutaneous Immunotherapy With Viaskin Peanut in Peanut-allergic Children</scientifictitle>
    <utrn />
    <trialacronym>PEPITES</trialacronym>
    <secondaryid>PEPITES</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Peanut Allergy</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Allergies</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Viaskin Peanut 250mcg
Other interventions - Placebo

Experimental: Viaskin Peanut 250mcg - 

Placebo Comparator: Placebo - 


Other interventions: Viaskin Peanut 250mcg
Peanut extract cutaneous patch

Other interventions: Placebo
Cutaneous patch containing an inactive deposit manufactured to mimic peanut extract

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of treatment responders in the overall population - A subject is defined as a treatment responder if:
The initial eliciting dose (ED) was &gt;10 mg peanut protein and the ED is =1,000 mg peanut protein at the post treatment double-blind placebo controlled food challenge (DBPCFC), or
The initial eliciting dose (ED) was =10 mg and the ED is =300 mg peanut protein at the post-treatment DBPCFC.</outcome>
      <timepoint>Month 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of treatment responders in each of the 2 screening ED strata</outcome>
      <timepoint>Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline of mean and median cumulative reactive dose of peanut protein</outcome>
      <timepoint>Baseline and Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline of mean and median eliciting dose of peanut protein</outcome>
      <timepoint>Baseline and Month 12</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Main 

          1. Male or female children aged 4 through 11 years;

          2. Physician-diagnosis of peanut allergy or children with a well documented medical
             history of IgE-mediated symptoms after ingestion of peanut and currently following a
             strict peanut-free diet, but without a physician diagnosis;

          3. Peanut-specific IgE level (ImmunoCAP system) &gt;0.7 kU/L;

          4. Positive peanut skin prick test (SPT) with a largest wheal diameter:

               -  =6 mm for children 4 through 5 years of age at Visit 1,

               -  =8 mm for children 6 years and above at Visit 1;

          5. Positive DBPCFC at =300 mg peanut protein.

        Main</inclusivecriteria>
    <inclusiveminage>4</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>11</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. History of severe anaphylaxis to peanut with any of the following symptoms:
             hypotension, hypoxia, neurological compromise (collapse, loss of consciousness or
             incontinence);

          2. Generalized dermatologic disease

          3. Diagnosis of mast cell disorders, including mastocytosis or uricaria pigmentosa as
             well as hereditary or idiopathic angioedema;

          4. Diagnosis of asthma that fulfills any of the following criteria:

               -  Uncontrolled persistent asthma as defined by National Asthma Education and
                  Prevention Program Asthma guidelines 2007 or by Global Initiative for Asthma
                  guidelines 2015,

               -  Asthma treated with either a high daily high dose of inhaled corticosteroid or
                  with a combination therapy of a medium or high daily dose of inhaled
                  corticosteroid with a long acting inhaled ß2 agonist or with a combination
                  therapy of a high daily dose of inhaled corticosteroid with a long acting inhaled
                  ß2 agonist. Asthmatic subjects treated with a medium daily dose of inhaled
                  corticosteroids are eligible. Intermittent asthmatic subjects who require
                  intermittent use of inhaled corticosteroids for rescue are also eligible,

               -  Two or more systemic corticosteroid courses for asthma in the past year or 1 oral
                  corticosteroid course for asthma within 3 months prior to Visit 1, or during
                  screening period,

               -  Prior intubation/mechanical ventilation for asthma within 1 year prior to Visit
                  1, or during screening;

          5. Receiving ß-blocking agents, angiotensin-converting enzyme inhibitors,
             angiotensin-receptor blockers, calcium channel blockers or tricyclic antidepressant
             therapy;

          6. Received anti-tumor necrosis factor drugs or anti-IgE drugs (such as omalizumab) or
             any biologic immunomodulatory therapy within 1 year prior to Visit 1, during screening
             period or during study participation;

          7. Use of systemic long-acting corticosteroids within 12 weeks prior to Visit 1 and/or
             use of systemic short-acting corticosteroids within 4 weeks prior to Visit 1 or during
             screening;

          8. Prior or concomitant history of any immunotherapy to any food;

          9. Receiving or planning to receive any aeroallergen immunotherapy during their
             participation in the study. Aeroallergen immunotherapy must be discontinued at the
             time of Visit 1;

         10. Any disorder in which epinephrine is contraindicated such as coronary artery disease,
             uncontrolled hypertension, or serious ventricular arrhythmias.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>356</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>18/08/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Allergy Medical - Brisbane</hospital>
    <hospital>Princess Margaret Hospital for Children - Perth</hospital>
    <hospital>Children's Hospital Westmead - Sydney</hospital>
    <postcode> - Brisbane</postcode>
    <postcode> - Perth</postcode>
    <postcode> - Sydney</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bonn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Erlangen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Cork</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>DBV Technologies</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The PEPITES study evaluates the efficacy and safety of Viaskin Peanut 250 µg peanut protein
      to induce desensitization to peanut in peanut-allergic children 4 through 11 years of age
      after a 12-month treatment by epicutaneous immunotherapy (EPIT).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02636699</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>